Mediwound Ltd (MDWD) News & EventsMDWDMediwound Ltd

MediWound Enters Underwriting Agreement with H.C. Wainwright for 1.2M Shares

MediWound Ltd. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., under which the underwriter has agreed to purchase on a firm commitment basis 1.2M ordinary shares of MediWound, at a price to the public of $12.50 per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 5, subject to satisfaction of customary closing conditions. MediWound intends to use the net proceeds from the offering for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

MediWound Secures Additional $3.3M Funding from DOW

MediWound announced that the U.S. Department of War, DOW, has awarded the Company an additional $3.3M in non-dilutive funding to advance the development of a room-temperature-stable formulation of NexoBrid as a non-surgical debridement solution for battlefield burn care. The supplemental award raises the total program budget to $21.8M. The program is intended to support development of the room-temperature-stable formulation through submission of an IND application to the U.S. Food and Drug Administration.

MediWound VALUE Study Safety Review Completed

On September 14, MediWound announced that the independent Data and Safety Monitoring Board completed its pre-specified periodic safety review of the ongoing Phase III VALUE study evaluating the safety and efficacy of EscharEx in patients with venous leg ulcers. Following its review, the DSMB did not identify any safety concerns and recommended that the study continue as planned without modification, the company announced. MediWound also continues to expect the study's pre-specified interim sample-size reassessment and completion of patient enrollment by the end of the first quarter of 2027, it noted. "We are encouraged by the DSMB's recommendation to continue the VALUE study as planned and without modification. The DSMB's findings are consistent with the favorable safety profile observed across the EscharEx clinical program and support our continued execution of this pivotal Phase III study," said Ofer Gonen, Chief Executive Officer of MediWound.